Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended December 31, 2025. The company highlighted continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, along with a completed leadership transition and corporate rebranding.
The company ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized its strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026.
Company Background and Approach
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is a clinical-stage pharmaceutical company committed to developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
The company operates in Canada, the United States, the United Kingdom, and Ireland.
Clinical Programs
HLP003, a proprietary NSA, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. Helus Pharma aims to improve the treatment landscape through the introduction of NSAs intended to provide durable improvements in mental health.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110738234/Biomednewsbreaks-Helus-PharmaTM-NASDAQ-HELP-Cboe-CA-HELP-Reports-Q3-2025-Results-Advances-Phase-3-And-Phase-2-Programs